Publications

Anti-Tumor Activity of Debio 0123 in Combination with Sacituzumab Govitecan in Preclinical Models of Breast Cancer

Impact of food and high gastric pH on the bioavailability of the WEE1 inhibitor Debio 0123 assessed in a phase…

Preclinical Characterization of DPI-4452: A 68Ga/177Lu Theranostic Ligand for Carbonic Anhydrase IX

First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX–Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma

Debio 0123, a selective, brain penetrant WEE1 inhibitor in clinical development for patients with solid tumors

A Phase 1/2 study of the WEE1 inhibitor Debio 0123 in combination with temozolomide +/– radiotherapy in adults with recurrent…

The Multilink(TM) Linker is a promising approach to improve efficacy and safety of ADC’s

Evaluation of the microbiota-sparing properties of the anti-staphylococcal antibiotic afabicin

First-in-human clinical trial design of a first-in-class theranostic approach with a peptide-based radioligand targeting CAIX-expressing tumors